Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177399 | 0.90 | JAK2 (0.52) | MAPTKMT2ALMNANUDT1BACE1 | |
| SCHEMBL10176976 | 0.90 | KMT2A (0.66) | MAPTKMT2ALMNAPPARGHPGD | |
| SCHEMBL22777751 | 0.79 | BACE1 (0.50) | MAPTKMT2ASMN1; SMN2NUDT1BACE1 | |
| SCHEMBL10176974 | 0.78 | CNR2 (0.47) | KMT2ALMNAPPARGHPGDSMN1; SMN2 | |
| SCHEMBL7976705 | 0.77 | HDAC1 (0.54) | NUDT1BACE1THRBRECQLHDAC1 | |
| SCHEMBL13259209 | 0.77 | KMT2A (0.63) | KMT2AHPGDSMN1; SMN2NUDT1BACE1 | |
| SCHEMBL11205958 | 0.77 | MAPT (0.55) | MAPTKMT2ASMN1; SMN2NUDT1BACE1 | |
| SCHEMBL13677252 | 0.76 | KMT2A (0.51) | MAPTKMT2ALMNASMN1; SMN2NUDT1 | |
| Ammonia Solution, Strong SCHEMBL5312050 | 0.76 | MAPT (0.77) | MAPTKMT2ALMNAHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7974097 | 0.76 | HDAC1 (0.53) | NUDT1BACE1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | MAPT 738/4885KMT2A 453/4885LMNA 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.